Median PFS (95% CI) was 8.38 months (2.73–not calculable [NC]), 8.28 months (2.60–NC), 2.37 months (0.46–2.69), and 2.66 months (0.43–2.99) in cHL anti‐PD‐1/PD‐L1 naïve, cHL anti‐PD‐1/PD‐L1 progressors, DLBCL, and PTCL cohorts, respectively (Figure 2). This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.